Organon & Co | OGN - Current Assets



Organon & Co reported $4.62B in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
Adcock Ingram Holdings ZAR 5.12B 234.71M Dec/2024
Bristol-Myers Squibb USD 33.22B 2.44B Jun/2025
Celltrion KRW 5.46T 122.95B Mar/2025
Cspc Pharmaceutical CNY 21.89B 4.58B Dec/2024
Dianthus Therapeutics USD 263.6M 17.3M Jun/2025
Divis Laboratories Ltd 100.81B 7.4B Mar/2025
Gilead Sciences USD 14.72B 2.18B Jun/2025
Glaxosmithkline GBP 17.67B 676M Jun/2025
Kangmei Pharma CNY 6.9B 6.92M Jun/2025
Knight Therapeutics CAD 397.57M 36.96M Sep/2024
Laboratorios Farma EUR 516.3M 26.69M Jun/2025
Malin Corporation EUR 62.6M 26.7M Dec/2024
Medical Developments International AUD 33.41M 7.26M Dec/2024
Merck USD 37.07B 1.56B Jun/2025
Neuren Pharmaceuticals AUD 399.33M 171.29M Dec/2024
Novartis USD 25.94B 3.76B Jun/2025
Organigram Holdings CAD 277.78M 46.29M Jun/2025
Organon & Co USD 4.62B 247M Jun/2025
Pharma Mar EUR 249.4M 13.39M Jun/2025
Qiagen NV USD 1.82B 76.12M Jun/2025
Sartorius EUR 2.17B 7.5M Jun/2025
Sino Biopharmaceutical CNY 24.69B 536.66M Dec/2024
Tilray USD 707.34M 18.54M Nov/2024